DNA Methylation and the Cancer Epigenome Biological and Translations Implications

Video   Jan 01, 2014

 

About the Speaker

Stephen B. Baylin, M.D., is deputy director of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Virginia and D.K. Ludwig professor of oncology and medicine. He is chief of the Cancer Biology Division and associate director for research of the center.


Abstract

Genome-wide mapping studies are dramatically contributing to remarkable increases in our understanding of epigenetic abnormalities in cancer.  Abnormal DNA methylation, both losses and gains, and key associated chromatin changes may largely affect  distinct  genomic  regions which contain nuclear lamin associated,  late replicating DNA , enriched for  low transcription, developmental, genes  with promoter region, “bivalent” chromatin .  Such chromatin, in embryonic and adult stem cells, is essential for maintenance of the stem cell state.  Furthermore, in multiple tumor types, frequent mutations are being found in genes which control normal epigenomes.  While the phenotypic consequences of these largely remain to be dissected, mutations in the IDH1 and 2 genes, and in the Tet family of proteins which trigger steps for active DNA de-methylation, are now linked to DNA methylation and chromatin alterations associated with abnormal gene silencing.  Importantly, multiple of the above epigenetic abnormalities are being found in cancer-risk states which involve chronic inflammation and attendant increases in reactive oxygen species (ROS).  Finally, all of the above biology has exciting translational implications for the concepts of “epigenetic therapy” for cancer and molecular signatures which can guide such treatments and also be useful for cancer diagnosis and staging.

 
 
 
 

Recommended Videos

Study Shows HPV-vaccine Against Cervical Cancer is Working

Video

Girls in the first birth cohort to be offered and receive the HPV vaccine showed a lower degree of dysplasia which may eventually lead to cervical cancer than a birth cohort from 1983. This is the conclusion of a new study conducted by researchers at the University of Copenhagen, who have been the first to study the vaccine’s effect on the general population.

WATCH NOW

Targeting Tumors: Challenges of Antibody-Drug Conjugates

Video

More than two dozen ADCs are currently being used in the clinic to treat diseases like Hodgkin's lymphoma and breast cancer, and researchers are developing many more. But it's taken decades to find the right combination of drug, antibody target and linker, and then make sure the right amount of ADC hits the tumor.

WATCH NOW

How Gene Editing Can Change an Entire Species

Video

In a TedTalk, journalist Jennifer Kahn discusses exciting technology that utilizes the gene editing technology CRISPR to try and achieve a grand goal: eradicating malaria and zika through the development of resistant mosquitoes.

WATCH NOW

 

Comments | 0 ADD COMMENT

Like what you just watched? You can find similar content on the communities below.

Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy